HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Teva, Bausch & Lomb receive tentative ANDA approval for generic versions of Rogaine.

This article was originally published in The Rose Sheet

  • News
  • The Rose Sheet

Executive Summary

TEVA, BAUSCH & LOMB RECEIVE TENTATIVE APPROVAL TO MARKET GENERIC ROGAINE beginning on Feb. 13, when Pharmacia & Upjohn's patent for the topical minoxidil 2% hair loss treatment expires. Teva's generic subsidiary Lemmon received the first tentative abbreviated new drug approval (ANDA) for topical minoxidil on Dec. 15; Bausch & Lomb Pharmaceuticals received tentative approval on Dec. 22.

Table

View full table

Tags:
Latest Headlines

Beiersdorf Partners With Biopharma For Anti-Aging Skin Care Innovation; Beauty Business News

Clasado, Probi Funded Study Shows Synergistic Effect Of Synbiotic Combination

Qunol Acquisition Gets Sanofi CHC Off To Flying Start

Walmart Lays Out Expectations For Beauty Brands' MoCRA Compliance

See All
UsernamePublicRestriction

Register

RS002358

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By